Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Request Sample

Polycystic ovary syndrome can be explained as set of symptoms such as insulin sensitivity, menstrual regulatory, infertility, acne, and excess body and facial hair, which occurs due to increased levels of male hormone i.e. androgens in females of child-bearing age (15 to 49 years).

Statistics:

The global polycystic ovary syndrome treatment market is estimated to account for US$ 945.1 Mn in terms of value and is expected to reach US$ 1,311.0 Mn by the end of 2027.

Global Polycystic Ovary Syndrome Treatment Market: Drivers

High prevalence of polycystic ovary syndrome is expected to propel growth of the global polycystic ovary syndrome treatment market over the forecast period. For instance, according to the study ‘The prevalence of polycystic ovary syndrome in adolescents: A systematic review and meta-analysis’, published in September 2019, the prevalence of polycystic ovarian syndrome in adolescents based on the Rotterdam criteria was 11.04%, based on the National Institute of Health criteria, it was 3.39%, and based on Androgen Excess and Polycystic Ovary Syndrome Society, it was 8.03%.

Moreover, R&D in polycystic ovary syndrome is also expected to aid in growth of the market. For instance, in June 2020, ‘Distinct subtypes of polycystic ovary syndrome with novel genetic associations: An unsupervised, phenotypic clustering analysis’ – a study funded by the National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and National Institute of Diabetes and Digestive and Kidney Diseases reported that polycystic ovary syndrome may have at least two different subtypes.

Statistics:

Insulin Sensitizing Agents held dominant position in the global polycystic ovary syndrome treatment market in 2019, accounting for 32.9% share in terms of value, followed by Aromatase Inhibitors & SERMs and Oral contraceptives, respectively.

Figure 1. Global Polycystic Ovary Syndrome Treatment Market Share (%), by Value, by Drug Class, 2019

Global Polycystic Ovary Syndrome Treatment Market: Restraints

Unavailability of FDA approved drugs is expected to hinder growth of the global polycystic ovary syndrome treatment market. Currently, there are no drugs approved by U.S. FDA and EMA for the direct treatment of polycystic ovary syndrome. Thus, physicians can only prescribe drugs for the management of off-label indications.

Moreover, adoption of alternative treatment options such as Ayurveda and Homeopathy is also expected to hinder growth of the global polycystic ovary syndrome treatment market.

Polycystic Ovary Syndrome Treatment Market Report Coverage Report Coverage Details Base Year: 2019 Market Size in 2019: US$ 904.7 Mn Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027 Forecast Period 2020 to 2027 CAGR: 4.8% 2027 Value Projection: US$ 1,311.0 Mn Geographies covered: North America: U.S., Canada

U.S., Canada Latin America: Brazil, Argentina, Mexico, Rest of Latin America

Brazil, Argentina, Mexico, Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe

Germany, U.K., Spain, France, Italy, Russia, Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific

China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific Middle East: GCC Countries, Israel, Rest of Middle East

GCC Countries, Israel, Rest of Middle East Africa: South Africa, North Africa, Central Africa Segments covered: By Drug Class: Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Diuretics.

Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs, Diuretics. By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Companies covered: Sanofi S.A., Amneal Pharmaceuticals, Inc., Laurus Labs Limited, Zydus Pharmaceuticals, Inc., Prasco Laboratories, Dr. Reddy's Laboratories, Cadila Pharmaceuticals, Novartis International AG, Concordia Pharmaceuticals Inc., Covis Pharmaceuticals, Inc., Cardinal Health, Aphena Pharma Solutions Tennessee, Inc., Mylan N.V., McKesson Corporation, Teva Pharmaceutical Industries Ltd, Lupin Pharmaceutical, and Sun Pharmaceutical Industries Ltd. Growth Drivers: High prevalence of polycystic ovary syndrome

Research and development Restraints & Challenges: Unavailability of FDA approved drugs

Alternative treatment options

Global Polycystic Ovary Syndrome Treatment Market: Opportunities

Entry into emerging markets is expected to offer lucrative growth opportunities for players in the global polycystic ovary syndrome treatment market. Pharmaceutical drugs manufacturers may focus on emerging economies in Asia Pacific and Africa to target large patient populations.

Moreover, effective reimbursement policies and reduction in costs is also expected to aid in growth of the market. Drugs used for the treatment of polycystic ovary syndrome are not covered in most coverage policies or health insurance. Cost of few drugs are comparatively high in the U.S. and Europe. Thus, reduction in cost of branded drugs would help the adoption of polycystic ovary syndrome therapeutics across the globe.

The global polycystic ovary syndrome treatment market was valued at US$ 904.7 Mn in 2019 and is forecast to reach a value of US$ 1,311.0 Mn by 2027 at a CAGR of 4.8% between 2020 and 2027.

Figure 2. Global Polycystic Ovary Syndrome Treatment Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

Market Trends/Key Takeaways

High prevalence of polycystic ovary syndrome in emerging economies is expected to propel growth of the global polycystic ovary syndrome treatment market over the forecast period. For instance, according to the review article, Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India, published in 2019, the prevalence of polycystic ovary syndrome in India ranges from 3.7 to 22.5 percent.

Moreover, R&D in polycystic ovary syndrome is also expected to aid in growth of the market. For instance, in April 2019, a study published in The Journal of Clinical Endocrinology & Metabolism reported identifying DENND1A, a gene involved in male hormone production, which plays a major role in the development of polycystic ovary syndrome.

Global Polycystic Ovary Syndrome Treatment Market: Competitive Landscape

Major players operating in the global polycystic ovary syndrome treatment market include, Sanofi, Novartis AG, Teva Pharmaceutical Industries Limited, Addex Therapeutics Ltd., BIOCAD, Merck KGaA, AstraZeneca plc., Bristol Myers Squibb Co., Ferring Pharmaceuticals, Inc., and Crinetics Pharmaceuticals, Inc.

Global Polycystic Ovary Syndrome Treatment Market: Key Developments

Major players in the global polycystic ovary syndrome treatment market are focused on adopting partnership strategies to expand their product portfolio. For instance, in January 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women's health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome.